Previous 10 | Next 10 |
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced th...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced th...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced ...
Aerie Pharmaceuticals (AERI) has completed patient enrollment for its first Phase 3 trial of netarsudil ophthalmic solution in Japan, comparing netarsudil ophthalmic solution 0.02%, administered once a day, to ripasudil hydrochloride hydrate ophthalmic solution 0.4%, marketed as Glanatec ...
Topline results expected in the fourth quarter of 2021 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma,...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced ...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced ...
Aerie Pharmaceuticals, Inc. (AERI) Q1 2021 Earnings Conference Call May 05, 2021, 05:00 PM ET Company Participants Ami Bavishi - Director of IR Vince Anido - Chairman and CEO Tom Mitro - President and COO Rich Rubino - CFO David Hollander - Chief Research and Development Officer John LaRocca ...
Aerie Pharmaceuticals (AERI): Q1 Non-GAAP EPS of -$0.72 misses by $0.04; GAAP EPS of -$0.91 beats by $0.01.Revenue of $22.97M (+12.9% Y/Y) misses by $0.1M.Press Release For further details see: Aerie Pharmaceuticals EPS misses by $0.04, misses on revenue
First Quarter 2021 Net Revenue Per Bottle of $89, up 11.3% over Fourth Quarter 2020 First Quarter 2021 Net Revenues of $23.0 Million Increased 12.9% over First Quarter 2020 Significant Progress Made Across the Pipeline Conference Call and Webcast Today, May...
News, Short Squeeze, Breakout and More Instantly...
Aerie Pharmaceuticals Inc. Company Name:
AERI Stock Symbol:
NASDAQ Market:
Aerie Pharmaceuticals Inc. Website:
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Al...
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceut...
NEW YORK, NY / ACCESSWIRE / October 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...